EE281 Cost-Effectiveness of Every Two Month Cabotegravir Long-Acting (CAB-LA) for Pre-Exposure Prophylaxis (PREP) Compared with Daily Oral Tenofovir Disoproxil Fumarate (TDF)/ Emtricitabine (FTC) As Prep to Prevent HIV-1 in the UK
Jun 1, 2024, 00:00
10.1016/j.jval.2024.03.580
https://www.valueinhealthjournal.com/article/S1098-3015(24)00695-8/fulltext
Title :
EE281 Cost-Effectiveness of Every Two Month Cabotegravir Long-Acting (CAB-LA) for Pre-Exposure Prophylaxis (PREP) Compared with Daily Oral Tenofovir Disoproxil Fumarate (TDF)/ Emtricitabine (FTC) As Prep to Prevent HIV-1 in the UK
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(24)00695-8&doi=10.1016/j.jval.2024.03.580
First page :
Section Title :
Open access? :
No
Section Order :
10059